Drug Search Results

Tegobuvir

Alternative Names: tegobuvir, gs-9190, gs9190, gs 9190
Latest Update: 2023-10-27
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HCV-NS5B Inhibitor,NN Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tegobuvir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis C, Chronic

Phase 2: Hepatitis A|Hepatitis C, Chronic|Communicable Diseases|Hepatitis C

Trial	Phase	Trial Status	Disease	Primary Completion Date
2009-013442-86	P3	Completed	Hepatitis C, Chronic	2014-05-29
2008-004527-31	P2	Completed	Hepatitis C, Chronic	2013-09-05
2010-023952-10	P2	Terminated	Hepatitis C, Chronic	2013-08-15
2010-020911-35	P2	Terminated	Hepatitis C, Chronic	2013-08-13

Recent News Events

Date	Type	Title
10/27/2023	PubMed	Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors.
03/22/2023	PubMed	Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.
03/13/2023	PubMed	Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions